Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant protein nanoparticle COVID-19 vaccine (AIM Honesty)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a recombinant protein nanoparticle vaccine candidate developed by AIM Honesty (a subsidiary of AIM Vaccine Co., Ltd.) for the prevention of COVID-19. The vaccine utilizes recombinant SARS-CoV-2 proteins, typically the spike protein or its receptor-binding domain (RBD), which are engineered into a nanoparticle format. This presentation mimics the natural structure of the virus to more effectively stimulate the immune system, inducing the production of neutralizing antibodies and activating cellular immune responses. As of the current pipeline information, the vaccine is in the preclinical stage of development.
- Other names
- recombinant nanoparticle protein COVID-19 vaccineSARS-CoV-2 recombinant protein nanoparticle vaccineSARS-CoV2 recombinant protein nanoparticle vaccineSARS-CoV 2 recombinant protein nanoparticle vaccinerecombinant nanoparticle protein COVID-19 vaccine-AIM Honesty-SARS-CoV-2-recombinant protein nanoparticle vaccine-COVID-19
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant protein nanoparticle COVID-19 vaccine (AIM Honesty).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant protein nanoparticle COVID-19 vaccine (AIM Honesty).